Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Возможности и перспективы Лодоза в леченииизолированной систолической артериальнойгипертензии
Возможности и перспективы Лодоза в леченииизолированной систолической артериальнойгипертензии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Полный текст
Список литературы
1. Epstein M, Bakris G. Newer approaches to antihypertensive therapy: use of fixed-dose combination therapy. Arch Intern Med 1996; 156: 1969–78.
2. Чазова И.Е., Бойцов С.А., Небиеридзе Д.В. Основные положения проекта второго пересмотра рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваскул. тер. и профилак. 2004; 4: 90–8.
3. Чазова И.Е., Бойцов С.А., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией. Методическое письмо МЗ РФ. М., 2004; 47.
4. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hyperstension: a critical review. J Clin Hypertension 1987; 3: 278–93.
5. Papdemetriou V, Prisant LM, Weber M et al. Low-dose combination therapy in the management of hypertension. Primary Cardiol 1995; 21: 29–31, 39.
6. Prisant LM, Weir MR, Papademetriou V et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995; 130: 359–66.
7. PA van Zweiten, Beneficial combinations of two or more antihypertensive drugs, European Society of Hypertension Scientific Newsletter; 2003; 4 (16).
8. Sa Cunha R, Pannier B, Benetos A et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15: 1423–30.
9. Delerme S. Amelioration pression-independante de la distensibilite des gros troncs arteriels par le traitement anti-hypertenseur (DEA de pharmacologie experimental et clinique). Paris: Universite Paris XI; 1997–1998.
10. Asmar R, Hugues C, Pannier B et al. Duration of action of bisoprolol after cessation of a 4 week treatment and its influence on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients. Eur Heart J 1987; 8: 115–20.
11. Benetos A, Consoli S, Safavian A et al. Efficacy, safety and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140 (4): E11.
12. Beevers DG. The end of blockers for uncomplicated hypertension? Lancet 2005; DOI: 1.
13. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.
14. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choise in the treatment of primary hypertension? A meta-analysis. Lancet 2005; DOI:10.1016/S0140-6736(05) 67573-3.
15. Cruikshank JM. The clinical importance of cardioselectivity and lipophilicity in beta-blockers. Am Heart J 1980; 100: 160–78.
16. Zillich AJ, Garg J, Basu S, Bakris GL et al. Thiazide Diuretics, Potassium, and the Development of Diabetes. A Quantitative Review. Hypertension 2006; 48 (2): 219–24.
17. Dequattro V, Weir MR. Bisoprolol fumarate/hydrochlorothiazide 6,25 mg: a new low dose option for first-line antihypertensive therapy. Adv Ther 1993; 10: 197–206.
18. Frishman WH, Bbryzinksi BS, Coulson LR et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1461–8.
19. Frishman WH, Burris JF, Mroczek WJ et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
20. Lewin AJ, Leug MC, Targum S et al. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6,25 mg combination in patients with mild to moderate hypertension. Clin Cardiol 1993; 16: 732–6.
21. Neutel JM, Rolf CN, Valentine SN et al. Low-dose combination therapy as first line treatment of mild to moderate hypertension: the efficacy and safety of bisoprolol/6,25 HCTZ versus amlodipine, enalapril and placebo. Cardiovasc Rev Rep 1996; 17: 33–45.
22. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003; 326: 1427.
2. Чазова И.Е., Бойцов С.А., Небиеридзе Д.В. Основные положения проекта второго пересмотра рекомендаций ВНОК по профилактике, диагностике и лечению артериальной гипертензии. Кардиоваскул. тер. и профилак. 2004; 4: 90–8.
3. Чазова И.Е., Бойцов С.А., Остроумова О.Д. Комбинированная терапия больных артериальной гипертонией. Методическое письмо МЗ РФ. М., 2004; 47.
4. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hyperstension: a critical review. J Clin Hypertension 1987; 3: 278–93.
5. Papdemetriou V, Prisant LM, Weber M et al. Low-dose combination therapy in the management of hypertension. Primary Cardiol 1995; 21: 29–31, 39.
6. Prisant LM, Weir MR, Papademetriou V et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995; 130: 359–66.
7. PA van Zweiten, Beneficial combinations of two or more antihypertensive drugs, European Society of Hypertension Scientific Newsletter; 2003; 4 (16).
8. Sa Cunha R, Pannier B, Benetos A et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15: 1423–30.
9. Delerme S. Amelioration pression-independante de la distensibilite des gros troncs arteriels par le traitement anti-hypertenseur (DEA de pharmacologie experimental et clinique). Paris: Universite Paris XI; 1997–1998.
10. Asmar R, Hugues C, Pannier B et al. Duration of action of bisoprolol after cessation of a 4 week treatment and its influence on pulse wave velocity and aortic diameter: a pilot study in hypertensive patients. Eur Heart J 1987; 8: 115–20.
11. Benetos A, Consoli S, Safavian A et al. Efficacy, safety and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J 2000; 140 (4): E11.
12. Beevers DG. The end of blockers for uncomplicated hypertension? Lancet 2005; DOI: 1.
13. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–9.
14. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choise in the treatment of primary hypertension? A meta-analysis. Lancet 2005; DOI:10.1016/S0140-6736(05) 67573-3.
15. Cruikshank JM. The clinical importance of cardioselectivity and lipophilicity in beta-blockers. Am Heart J 1980; 100: 160–78.
16. Zillich AJ, Garg J, Basu S, Bakris GL et al. Thiazide Diuretics, Potassium, and the Development of Diabetes. A Quantitative Review. Hypertension 2006; 48 (2): 219–24.
17. Dequattro V, Weir MR. Bisoprolol fumarate/hydrochlorothiazide 6,25 mg: a new low dose option for first-line antihypertensive therapy. Adv Ther 1993; 10: 197–206.
18. Frishman WH, Bbryzinksi BS, Coulson LR et al. A multifactorial trial design to assess combination therapy in hypertension: treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1461–8.
19. Frishman WH, Burris JF, Mroczek WJ et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182–8.
20. Lewin AJ, Leug MC, Targum S et al. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6,25 mg combination in patients with mild to moderate hypertension. Clin Cardiol 1993; 16: 732–6.
21. Neutel JM, Rolf CN, Valentine SN et al. Low-dose combination therapy as first line treatment of mild to moderate hypertension: the efficacy and safety of bisoprolol/6,25 HCTZ versus amlodipine, enalapril and placebo. Cardiovasc Rev Rep 1996; 17: 33–45.
22. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Brit Med J 2003; 326: 1427.
Авторы
С.В.Недогода
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.